Physician profile
Peter Kelly
NPI 1578853099
$620.53
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $579 · 2022: $41.96.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $165.81 | 2021-2022 | |
| Dova Pharmaceuticals | $152.55 | 2021 | |
| Janssen Biotech, INC. | $129.65 | 2021 | |
| Seagen INC. | $35.99 | 2021 | |
| Ge Healthcare | $25.09 | 2021 | |
| Celgene Corporation | $24.47 | 2021 | |
| Amgen INC. | $20.99 | 2021 | |
| Global Blood Therapeutics, INC. | $20.94 | 2021 | |
| Merck Sharp & Dohme LLC | $19.31 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $13.42 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.31 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Kelly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.